MTOR T1977K

CI-VAR-00004289Explore in graph →CIViC 2712

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Solid Neoplasm1
MTOR T1977K	Sirolimus	Predictive	D	Supports Sensitivity Response	3	submitted	EID7323 Sequencing data from 22 human kidney cancer cases was used to identify the activating mechanisms conferred by mTOR mutations. Cells that expressed activating mTOR mutants were sensitive to rapamycin t… (full text at CIViC) PMID 27482884 · Xu et al., 2016 · Open in CIViC	civic
Unmapped disease1unmapped disease
MTOR T1977K	(functional)	Functional	D	Supports Gain Of Function	2	accepted	EID9479 Public cancer genome sequencing data sets were used to generated a catalog of mTOR pathway mutations, identified 33 MTOR mutations which confer pathway hyperactivation. A single instance of T1977K was… (full text at CIViC) PMID 24631838 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.